X-linked Adrenoleukodystrophy
Conditions
Keywords
Adrenoleukodystrophy, Adrenomyeloneuropathy, Brain Diseases, Metabolic, Inborn, Central Nervous System Diseases, Demyelinating Diseases, White Matter Disorder, Genetic Diseases, X-Linked, Peroxisomal Disorders, Metabolic Diseases, Female Carrier, Adrenoleukodystrophy, women, Heterozygous Carrier, Quality of Life
Brief summary
X-linked adrenoleukodystrophy (X-ALD) is a hereditary white matter disorder caused by mutations in the ABCD1 gene leading to disturbances in the metabolism of fatty acids. This results in an accumulation of very long chain fatty acids (VLCFA) in the cells of the body causing damage to the central nervous system (white matter of the brain and spinal cord). The most common adult-onset X-ALD phenotype is adrenomyeloneuropathy (AMN), a slowly progressive myelopathic variant with demyelination of the long tracts in the spinal cord, clinically manifested as slowly progressive spastic paraparesis, sensory ataxia, bladder and sexual dysfunction. Although this rare disease is inherited X-linked, previous research revealed that up to 80% of heterozygous women develop AMN symptoms during their lifetime. The primary objectives of this study are 1) to assess the prevalence of symptomatic courses in female carriers of X-ALD and 2) to determine the impact of AMN symptoms on the quality of life of affected women in various areas (including everyday life, work, social network, sleep quality, sexuality, mood). Participants are asked to fill in self-report questionnaires, which are available in English, German, French, Spanish, and Italian, and are provided electronically on the online platform Leuconnect (https://www.leuconnect.com) launched by European Leukodystrophies Association (ELA) international (https://elainternational.eu/).
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* Informed consent obtained from the participant * Females ≥18 years at the time of consent, with proven X-ALD as defined by 1. Elevated VLCFA values, or 2. Mutation in ABCD1 gene
Exclusion criteria
* No informed consent and assent * Current pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants with AMN Symptoms as Assessed by Adult ALD Clinical Score (AACS) - self-report version | Day 0 |
| Quality of Life in Symptomatic versus Asymptomatic Participants as Assessed by Self-report Questionnaire (SF-36) | Day 0 |
Countries
Germany
Contacts
Leipzig University Medical Center, Leukodystrophy Outpatient Clinic, Department of Neurology, Leipzig, Germany